Literaturverzeichnis

1 Aapro MS. Controlling emesis related to cancer therapy. Europ J Cancer 1991 ;27:356–61 (Review)

2 Aapro MS. 5-HT3- receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1995;42**:** 551–68

3 Aapro MS, Sessa C, Thurlimann B. SAKK 90/95: A randomised double-blind trial to compare the clinical efficacy of granisetron to metoclopramide, both combined to dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Proc Ann Soc Clin Oncol 2000; 19: 600a

4 Agundez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57:265-69

5 Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
J Pharmacol Exp Ther 1996; 278**:** 441–46

6 Andrews PL, Hawthorn J. The neurophysiology of vomiting. Baillieres Clinical Gastroenterology 1988; 2:(1) 141–68

7 Andrews PLR, Davidson HIM. Activation of vagal afferent terminals by 5-hydroxytryptamine is mediated by the 5-HT3-receptor in the anaesthetized ferret.
J Physiol 1990; 422: 92 P

8 Andrews PLR , Davis CJ. The mechanism of emesis induced by anti-cancer therapy. In: Andrews PLR , Sanger GJ eds. Emesis in anti-cancer therapy. London: Chapman and Hall 1993: 113–61

9 Andrews PLR , Rapeport WG , Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy . Trends Pharmacol Sci 1988; 9: 334–41

10 Andrykowski MA. Definitial issues in the study of anticipatory nausea in cancer chemotherapy. J Behav Med 1986; 9: 33–41

11 Andrykowski MA, Jacobsen PB, Marks E et al. Prevalence, predictors and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer . Cancer 1988; 62: 2607–613

12 Antiemetic subcommittee of the Multinational Association of Supportive Care in Cancer: Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 1998; 9: 811–19

13 Aynacioglu AS, Sachse C, Brockmöller J et al. Allele frequencies of CYP2D6 and CYP2C19 in a Turkish population. Poster. Microsomes, Drug Oxidation and Clinical Pharmacology, Berlin , Sept.1997: 20–21

14 Aynacioglu AS; Sachse C; Bozkurt A et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol 1999; 66: 185–92

15 Bathum L, Johansson I, Ingelman-Sundberg M, Horder M, Brosen K. Ultrarapid metabolism of sparteine : frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment lenght polymorphism and long polymerase chain reaction. Pharmacogenetics 1998; 8: 119–23

16 Berger AM, Clark–Snow RA. Nausea and vomiting. In : De Vita VT , Hellman S Rosenberg SA eds.: Cancer : Principles and Practice of Oncology . Fifth Edition. Philadelphia Lippincott-Raven Publishers 1997: 2705–714

17 Bernal ML, Sinnes B, Johansson I, Mc Lellan R, Dahl ML, Ingelman-Sundberg M. High frequency of subjects with multiple CYP2D6 genes in a North-Spanish population. Eur J Clin Pharmacol 1997 ; 52 (Suppl) :A160

18 Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state knowledge of Cytochromes P450(CYP)2D6 and 2C19. Clin Pharmacokinet 1995;29 (3): 192-209

19 Bhandari P, Andrews PL. Preliminary evidence for the involvement of the putative 5-HT4-receptor in zacopride- and copper sulphate-induced vomiting in the ferret. Eur J Pharmacol 1991 ; 204: 273–80

20 Bleiberg H. A new class of antiemetics : the NK-1 receptor antagonists. Curr Opin Oncol 2000; 12 (4): 284–88

21 Bleiberg H, Van Belle S, Paridaens R, De Wasch G, Dirix LY, Tjean M . Compassionate use of a 5-HT3-receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment. Drugs 1992; 43 (Suppl 3): 27–32

22 Bloomer JC, Baldwin SJ, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. . Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Pharmacol 1994; 38: 557-66

23 Blower PR. 5-HT3 receptor antagonists and the cytochrome P450 system – clinical implications . Cancer 2000; 8: 405-14

24 Blower PR, Aapro M. Granisetron vs ondansetron : is it a question of duration of 5-HT3 receptor blockade ? Br J Cancer 2002; 86: 1662–663

25 Brockmöller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B, Roots I. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 4: 438–52

26 Brosen K, Gram LF, Haghfelt T, Bertilsson L. Extensive metabolizers of debrisoquine become poor metabolizer during quinidine treatment. Pharmacol Toxicol 1987; 60: 312–14

27 Bruntsch U, Drechsler S, Eggert J, Grosse H, Ukena D, Imhoff W, Färber L. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents. Seminars Oncology 1994; 5 (Suppl 9): 7–11

28 Bruntsch U , Rufenacht E, Parker J, Drechsler S, De Bruijn K. Tropisetron in the prevention of chemotherapy-induced nausea and vomiting in patients responding poorly to previous conventional antiemetic therapy. Ann Oncol 1993; 4: 25–29

29 Casper J, Schmoll H. Therapie von chemotherapiebedingter Übelkeit und Erbrechen. Arzt und Krankenhaus 1994; 10: 313–25

30 Clark RA, Gralla RJ. Delayed emesis: a dilemma in antiemetic control . Support Care Cancer 1993; 1: 182–85

31 Cooper S, Georgiu V. The impact of cytotoxic chemotherapy – perspectives from patients, specialists and nurses. Eur J Cancer 1992; 28 A (Suppl.1): 536–38

32 Corrigan BW, Nicholls B,Thakrai B. Heterogeneity in systemic availability of ondansetron and granisetron following oral administration. Drug Metab Dispos 1999; 27: 110 –12

33 Cubeddu LX. Mechanisms by which cancer chemotherapeutic drugs induce emesis.Seminars in Oncology 1992; 19 (Suppl.15): 2–13

34 Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032 F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322: 810–16

35 Cupissol DR, Serrou B, Canbel M. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer 1990; 26 (Suppl 1) , S23–S27

36 Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274: 516–20

37 Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992; 51 (1): 12–17

38 Daly AK, Brockmöller J, Broly F et al. Nomenclature for human CYP2D6 alleles Pharmacogenetics 1996; 6: 193–201

39 Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen VM. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 1996; 6: 319–28

40 Daly AK, Leathart JB, London SJ, Idle JR. An inactive cytochrome P450 (CYP2D6) allele containing a deletion and a base substitution. Hum Genet 1995; 95 (3): 337 -41

41 De Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, Verweij J. Patient perceptions of the side-effects of chemotherapy: the influence of 5-HT_3-Antagonists.Brit J Cancer 1997; 76 (8): 1055– 61

42 De Bruijn KM. The development of tropisetron in its clinical perspective. Ann Oncol 1993; 4: 19–23

43 Del Favero A, Roila F, Tonato M. Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities. Drug Safety 1993; 9: 410–28

44 De Mulder PHM, Seynave C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834-40

45 Dixon CM, Colthup PV, Serabit-Singh CJ, Kerr BM, Boehlert CC, Park GR, Tarbit MH. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995; 23: 1225-30

46 Dogliotti L, Antonacci RA, Paze E, Ortega C, Berruti A, Faggiulolo R. Three years experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. Drugs 1992; 43 (Suppl.3): 6-10

47 Drechsler S, Bauer R. 5-HT3-Rezeptorantagonisten. Arzneimitteltherapie 1995; 13: 224–35

48 Eichelbaum M, Mineshita S, Ohnhaus EE. The influence of enzyme induction on polymorphic sparteine oxidation. Brit J Clin Pharmacol 1986; 22: 49-53

49 Evans WE, Relling MV. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratios to discriminate reliably heterozygous and homozygous extensive metabolizers. Pharmacogenetics 1991; 1 (3):143-48

50 Fauser AA, Duclos B, Chemaissani A. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer 1996; 32A: 1523-29

51 Fauser AA, Fellhauer M, Hoffmann M. Guidelines for antiemetic therapy: Acute emesis. Europ J Cancer 1999; 35: 361-70

52 Fiore JJ, Gralla RJ. Pharmacological treatment of chemotherapy-induced nausea and vomiting. Cancer Invest 1984; 2: 351-61

53 Firkusny L, Krömer HK, Eichelbaum M. In vitro characterization of cytochrome P450 catalyzed metabolism of the antiemetic tropisetron. Biochem Pharmacol 1995; 49: 1777-84

54 Fischer V, Baldeck JP, Tse FL. Pharmacokineticsm and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans. Drug Metab Dispos 1992; 20: 603-07

55 Fischer V, Vickers AE, Heitz F, Mahadevan S, Baldeck JP, Minery P, Tynes R. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamin-antagonists, tropisetron and ondansetron. *Drug Metab Dispos* 1994; 22: 269-74

56 Fletcher CV, Acosta EP, Strykowski JM. Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health 1994; 15: 619-29

57 Fredrikson M, Husti T, Steineck G, Fürst C, Börjeson S, Peterson C. Delayed chemotherapy-induced nausea augmented by high levels of endogeneous noradrenaline . Brit J Cancer 1994; 70: 642-45

58 Freeman AJ, Cunningham KT, Tyers MB. Selectivity of 5-HT_3-receptor antagonists and antiemetic mechanisms of action. Anticancer Drugs 1992; 3: 79-85

59 Fukui HM, Yamamoto T, Ando S, Sasaki S, Sato S. Increase in serotonin levels in the dog ileum and blood by cisplatin as measured by microdialysis . Neuropharmacology 1993; 32: 959-68

60 Fukui HM, Yamamoto M, Sasaki S, Sato S. Possible involvement of peripheral 5-HT4 receptors in copper sulfate – induced vomiting in dogs. Eur J Pharmacol 1994; 257: 47-52

61 Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991; 48**:** 943-59

62 Gleiter CH, Gundert-Remy U. Gender differences in pharmacokinetics. Eur J Drug Metab Pharmacokinetics 1996; 21: 123–28

63 Goedehals L, Heron JF, Kleisbauer JP, Pagani O, Sessa C. Control of delayed nausea with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double blind, placebo-controlled, comparative study. Ann Oncol 1998; 9: 661-66

64 Gralla RJ. Current issues in the management of nausea and vomiting. Ann Oncol 1993; 4 (Suppl.3): S3-S7

65 Gralla RJ, Clark RA, Kris MG, Tyson LB. Methodology in anti-emetic trials . Europ J Cancer 1991; 27 (Suppl 1): S5-S8

66 Gralla RJ, Navari RM, Hesketh PJ. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998; 16: 1568-73

67 Gralla RJ, Osoba D, Kris MG. Recommendations for the use of antiemetics: evidence-based, clinical tractic guidelines. J Clin Oncol 1999; 17: 2971-94

68 Graves T. Emesis as a complication of cancer chemotherapy : pathophysiology, importance and treatment. Pharmacotherapy 1992; 12: 337-45

69 Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting.A comparison of their pharmacology and clinical efficacy. Drugs 1998; 55: 173-89

70 Griese EK, Zanger UM, Brudermans U et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8: 15-26

71 Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther Drug Monit 2002; 24 (3): 436–37

72 Hainsworth JD. Development of serotonin antagonists for the control of chemotherapy – induced emesis. Semin Surg Oncol 1993; 9: 279-84

73 Harris RZ, Benet LZ, Schwarz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50: 222–39

74 Hesketh PJ. Treatment of chemotherapy-induced emesis in the 1990s : improvement by the 5-HT3 receptor antagonists.Support Care Cancer 1994; 2 (5): 286–92

75 Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens : relevance to clinical practice. *Oncologist* 1999; 4 (3): 191–96

76 Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000; 18 (2): 163-73

77 Hesketh PJ. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer 2001; 9: 350-54

78 Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991; 83: 613-20

79 Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15 (1): 103-09

80 Hesketh PJ, Van Belle S, Aapro M et al. Differential involvement of neurotransmitters trough the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003; 39: 1074-80

81 Hoyer D, Clarke DE, Fozard JR et al. VII. International Union of pharmacology classification of receptors for 5-Hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46: 157 -203

82 Ingelman-Sundberg M, Oscarsson M, Mc Lellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 342-49

83 Italian Group for Antiemetic Research: Dexamethasone, granisetrone or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332: 1-5

84 Italian Group for Antiemetic Research: double – blind , dose – finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 1998; 16: 2937-42

85 Italian Group for Antiemetic Research : Dexamethasone alone or combined with ondansetron in the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000; 342: 1554-59

86 Johansson I, Lundquist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Nat Acad Sci 1993; 90: 11825-29

87 Johansson I, Oscarsson M, Yue QY, Bertilsson F, Sjöqvist F, Ingelman-Sundberg M.Genetic analysis of the Chinese cytochrome P450D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation .Mol Pharmacol 1994; 46: 452-59 (Abstract)

88 Junker A. Antiemetika bei Übelkeit und Erbrechen, induziert durch Zytostatika . Krankenhauspharmazie 1999; 5: 170-76

89 Junker A, Feyerabend T, Wiedemann GJ, Illiger HJ. Zytostatika- oder Strahlentherapie-induzierte Übelkeit und Erbrechen. Onkologe 2000; 6: 244-53

90 Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine.J Biol Chem 1990; 265: 17209-214

91 Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay BB, Possinger K, Roots I, Brockmöller J. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to Cytochrome P450 2D6 genotypes. J Clin Oncol 2002; 20: 2805-11

92 Kharasch ED, Russell M, Garton K, Lentz G, Bowdle TA, Cox K. Assessment of cytochrome P4503A4 activity during the menstrual cycle using alfentamil as a noninvasive probe. Anaesthesiology 1997; 87: 26-35

93 Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and isolation of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Amer J Human Genet 1989; 45: 889-904

94 Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S. Controlling delayed vomiting: double-blind, randomised trial comparing placebo , dexmethasone alone and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 108-14

95 Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A, Hesketh PJ. Use of NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Canc Inst 1997; 89 817-18

96 Kris MG, Roila F, De Mulder PHM, Marty M. Review article : Delayed emesis following anticancer chemotherapy. Supportive Care Cancer Abstract Volume 1998; 6: 228-32

97 Kutz K. Pharmacology, toxicology and human pharmacokinetics of tropisetron . Ann Oncol 1993; 4 (Suppl 3): 15–18

98 Laine K, Tybring G, Hartter S, Andersson K, Svensson JO, Widen J, Bertilsson L. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortrxptiline pharmacokinetics and the debrisoquine test. Clin Pharmacol Ther 2001; 70: 327–35

99 Legrand-Andreoletti M, Stucker I, Marez D et al. Cytochrome P450 (CYP2D6) gene polymorphism and lung cancer susceptibility in Caucasians. Pharmacogenetics 1998; 8 7-14

100 Lofters WS, Pater JL, Zee B. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997; 15: 2966-73

101 Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Letters 1996; 392: 30-34

102 Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 gene. Gene 1999; 226: 327-38

103 Mantovani G, Maccio A, Carreli L. Comparison of oral 5-HT3-receptor antagonists and low dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin. Oncol Rep 1998; 5: 273-80

104 Marez D, Legrand M, Sabbagh N, Lo-Guidice JM, Boone P, Broly F. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine .
Hum Genet 1996; 97: 668-70

105 Marez D, Legrand M, Sabbagh N et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population : characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7: 193-202

106 Marez D, Sabbagh N, Legrand M, Lo-Guidice JM, Boone P, Broly F. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics 1995; 5: 305-11

107 Martoni S, Angelelli B, Guaraldi M, Strocchi E, Pannuti F. Granisetron (GRA) vs. ondansetron (OND) in the prevention of cisplatinum-induced emesis: an open randomized cross-over study (abstract). Am Soc Clin Oncol 1993; 13: 431

108 Mc Elroy S, Sachse C, Brockmöller J et al. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS Pharm Sci 2000; 2: E33

109 Mc Lellan RA, Oscarsson M, Seidegard J, Evans DA, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997; 7: 187-91

110 Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics ? Clin Pharmacokinet 2002; 41: 329-42

111 Milano S, Simon C, Grelot L. In vitro release and tissue release of ileal serotonin after cisplatin induced emesis in the cat. Clinics in Autonomic Res 1991; 1: 275- 80

112 Miller AD. Central mechanisms of vomiting. Dig Dis Sci 1999; 44 (Suppl.): 39-43

113 Miller AD, Leslie RA. The area postrema and vomiting. Front Neuroendocrinology 1994; 15: 301–20

114 Morrow GR, Dobkin PL. Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: Prevalence , etiology, and behavioural interventions . Clin Psychol Rev 1988; 8: 517-36

115 Morrow GR, Hickok JT, Rosenthal SN. Progress in reducing nausea and emesis. Comparisons of ondansetron (zofran), granisetron (kytril) and tropisetron (navoban) Cancer 1995; 76: 343-57

116 Navari RM, Gandara DR , Hesketh PJ. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995; 13: 1242 -48

117 Navari RM. Use of placebos in delayed-emesis studies. J Clin Oncol 1999; 17: 1644-49

118 Navari R, Gralla RJ, Hesketh P. L–754,030, a selective Neurokinin-1 antagonist, reduces cisplatin-induced acute and delayed emesis : a double blind, randomized trial . Proc Am Soc Clin Oncol 1998; 17: 197-207

119 Navoban Product Information; Novartis Pharma , Basel , Switzerland

120 Nitta Y, Nishibori M, Iwagaki H et al. Changes in serotonin dynamics in the gastrointestinal tract of colon-26-tumour-bearing mice: effects of cisplatin treatment. Naunyn Schmiedeberg`s Arch Pharmacol 2001; 364: 329-34

121 Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995; 13: 1036-43

122 Perez EA. 5-HT3 antiemetic therapy for patients with breast cancer. Breast Cancer Res Treat 1999; 57 (2): 207-14

123 Perez EA, Hesketh PJ, Sandbach EJ. Comparison of single–dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy : a multicenter , double-blind , randomized parallel study. J Clin Oncol 1998; 16: 754-60

124 Possinger K, Späth-Schwalbe E, Kaiser R. Antiemetische Behandlung bei zytostatischer Chemotherapie. Dtsch Ärzteblatt 2001; 98: 924–27

125 Rademaker M. Do women have more adverse drug reactions ? Am J Clin Dermatol 2001; 2: 349–51

126 Roh HK, Dahl ML, Johansson J, Ingelman-Sundberg M, Cha YN, Bertilsson L. Debrisoquine and S-Mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996; 6: 441-47

127 Roila F, Del Favero A. Antiemetics revisited. Curr Opin Oncol 1997; 9 (4): 321-26

128 Roila F, Palladino MA, Ciccarese G, Basurto C. Recent improvements in antiemetic therapy. Tumori 1993; 83 (Suppl.2): S3-S14

129 Roila F, Tonato M, Basurto l. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomised double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1997; 5: 141-49

130 Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9: 675-78

131 Ruff P, Paska W, Goedehals L. Ondansetron compared with granisetron in the prophylaxis of cisplatin–induced acute emesis: a multicentre double-blind, randomized, parallel-group study. Oncology 1994; 51: 113–18

132 Sachse C, Brockmöller J, Bauer S, Reum T, Roots I. A rare insertion of T 226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype : CYP2D6*15. Pharmacogenetics 1996; 6 (3): 269-72

133 Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P4502D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Human Genet 1997; 60 (2): 284–95

134 Sachse C, Brockmöller J, Hildebrand M, Muller K, Roots I. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 1998; 8: 181–85

135 Sanwald P, David M, Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT_3 antagonists. Drug Metab Dispos 1996; 24: 603-09

136 Schwab M, Marx C, Zanger U, Eichelbaum M, Fischer-Bosch M. . Pharmakogenetik der Cytochrom P450 – Enzyme: Bedeutung für Wirkungen und Nebenwirkungen von Medikamenten. Dtsch Ärzteblatt 2002; 99: 497-504

137 Schwörer K, Racke K, Kilbinger H. Cisplatin increases the release of 5-hydroxytryptamine (5–HT) from the isolated vascularity perfused small intestine of the guinea-pig : involvement of 5-HT3 receptors. Naunyn Schmiedeberg's Arch Pharmacol 1991; 344: 143-49

138 Seynaeve C, De Mulder PHM, Verweij J. Pathophysiology of cytotoxic drug-induced emesis : Far from crystal-clear. Pharm Weekl Sci 1990; 13: 1-6

139 Smyth J F. Delayed emesis after high-dose cisplatin – the residual problem. Proc Eur Soc Med Oncol 1992; Nov 8**,** Lyon France

140 Sorbe B. Tropisetron in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. Ann Oncol 1993; 4: 39-42

141 Steijns LSW, Van der Weide J. Ultrarapid drug metabolism: PCR based detection of CYP2D6 gene duplication. Clin Chem 1998; 44: 914–17

142 Steward DJ. Cancer therapy, vomiting and antiemetics. Can J Physiol Pharmacol 1990; 68: 304-13

143 Stewart A, Mc Quade B, Cronje JDE. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicenter, double-blind, double-dummy randomized, parallel-group study. Oncology 1995; 52: 202–10

144 Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 1999; 24: 339–46

145 Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs 1996; 52 (5): 639–48

146 Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: a review . Ann Oncol 1991; 2: 107–14

147 Tonato M, Roila F, Del Favero A, Ballatori E. Antiemetics in cancer chemotherapy – historical perspective and current state of the art. Cancer 1994; 2: 150–60

148 Tonato M, Roila F, Del Favero A. Are there differences among the serotonin antagonists ? Support Care Cancer 1994*;* 2: 293-96

149 Tortorice PV, O'Connell MB. Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy 1990; 10: 129-45

150 Tremblay PB, Kaiser R, Sezer O, Rösler N, Schelenz C, Possinger K, Roots I, Brockmöller J. Variations in the 5-hydroxytryptamine type 3 B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003; 21: 2147–55

151 Tyers MB. Pharmacology and preclinical antiemetic properties of ondansetron Semi Oncol 1992; 4 (Suppl 10): 1–8

152 Tyers MB, Freeman AJ. Mechanisms of antiemetic activity of 5-HT_3 antagonists. Oncology 1991; 49: 263-68

153 Villikka K, Kivisto KT, Neuvonen PJ. The effect of rifampin on the pharmacokinetiks of oral and intravenous ondansetron. Clin Pharmacol Ther 1999; 65 (4): 377-81

154 Waldvogel HH. Antiemetische Therapie. Thieme-Verlag Stuttgart 1995

155 Watson JW, Gonsalves SF, Fossa AA, Mc Lean S, Seeger T, Obdach S, Andrews PLR. The antiemetic effects of CP-99,994 in the ferret and the dog: role of the NK_1 receptor. Brit J Pharmacol 1995; 115: 84-94

156 Wickham R. Nausea and vomiting. In : Yarbo CH, Frogge MH, Goodman M, eds: Cancer Symptom Management. 2nd Edition, Sudbury, Mass.: Jones and Bartlett Publishers 1999, 228-63

157 Wilder-Smith OHG, Borgeat A, Chappuis P, Fathi M, Forni M. Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 1993; 72: 2239-41

158 Wolf H. Preclinical and clinical pharmacology of the 5-HT_3 receptor antagonists. Scand J Rheumatol Suppl. 2000; 113: 37-45

159 Yalcin S, Tekuzman G, Baltali E. Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy : a randomized study. Amer J Clin Oncol 1999; 22: 94-96

160 Yamakuni H, Sawai H, Maeda Y et al. Probable Involvement of the 5-HT_4-Receptor in Methotrexat-Induced Delayed Emesis in Dogs. Pharmacology 2000; 292: 1002-07

161 Zofran (ondansetron hydrochloride) Injection and Tablets Product Information . Glaxo Wellcome Oncology/HIV. In: Physician`s Desk Reference . 52nd ed. , Montvale,NJ Medical Economics Company 1998, 1177-83